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SUMMARY – Pulmonary hypertension (PH) is a chronic disease which severely impairs quality 
of life (QoL). The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) is the first 
disease-specific tool to assess patient-reported symptoms, functioning and QoL in PH patients. The 
aim of this study was to adapt and validate the CAMPHOR for use in Croatia. The adaptation process 
involved three stages: translation (bilingual and lay panel), cognitive debriefing interviews with 
 patients and psychometric validation. For the latter stage, a postal survey was conducted with 50 
 patients to examine the reliability and validity of the adapted scale. All three scales of the Croatian 
CAMPHOR demonstrated excellent internal consistency (Symptoms = 0.93; Activity limitations = 
0.94; QoL = 0.92) and test-retest reliability correlations (Symptoms = 0.90; Activity limitations = 
0.95; QoL = 0.90). Predicted correlations with the SF-36 scales provided evidence for construct valid-
ity of the CAMPHOR scales. Evidence for known group validity was shown by the ability of the 
scales to distinguish between participants based on patient-perceived general health and disease sever-
ity. The Croatian version of the CAMPHOR is a valid and reliable tool for use in clinical routine and 
clinical research.
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Introduction
Pulmonary hypertension (PH) is an umbrella term 
which describes the pathophysiological state charac-
terized by elevation of the pulmonary artery pressure 
(PAP). It is diagnosed when the mean PAP is ≥25 mm 
Hg at rest1. The increase in pressure is progressive and 
leads to right ventricular failure2. The main symptoms 
of PH in the initial stages are nonspecific, such as ex-
ertional dyspnea, fatigue, angina, syncope or abdomi-
nal distension. Disease-specific pharmacotherapy can 
improve patient prognosis, but no cure is possible for 
primary PH3.
Traditionally, large-scale clinical trials in PH have 
relied on clinical outcomes as endpoints4, but these are 
impractical in everyday practice. The six-minute walk 
test (6MWT) has often been used as a primary 
 endpoint, yet the test is not capable of providing an 
accurate reflection of the patient experience of living 
with PH5.
More recently, clinical studies in PH have included 
health-related quality of life (HRQL) instruments such 
as the 36-item Short-Form Health Survey (SF-36)6-9, 
Ana Hećimović et al. Croatian validation and adaptation of CAMPHOR
4 Acta Clin Croat, Vol. 58, No. 1, 2019
EuroQoL9,10, and Nottingham Health Profile11. These 
measures focus on the measurement of symptoms and 
functioning12. However, generic instruments are of 
limited value as they are likely to miss issues pertinent 
to specific patient populations and include questions 
that are not relevant to different groups of respon-
dents13. Furthermore, these instruments demonstrate 
poor responsiveness14-16.
Pulmonary hypertension has a significant impact 
on the lives of patients, and PH-specific outcome 
measures are required to determine these effects accu-
rately. PH symptoms such as exertional dyspnea and 
fatigue have a major impact on physical activity, func-
tioning and working ability, which affects HRQL17. 
Associated conditions such as systemic sclerosis and 
side effects of pharmacological treatment (e.g., subcu-
taneous or parenteral prostacyclin) also affect HRQL 
of pulmonary arterial hypertension (PAH) patients. 
There is also the psychological impact of PAH, which 
includes feelings of social isolation. Approximately 
half of patients with PAH have symptoms of anxiety 
and about one-third experience symptoms of depres-
sion18.
The Cambridge Pulmonary Hypertension Out-
come Review (CAMPHOR) has been developed to 
assess both HRQL and quality of life (QoL) in pa-
tients diagnosed with PH19. Consequently, it provides 
an overall picture of how PH affects the lives of pa-
tients. The CAMPHOR is a needs-based outcome 
measure20. Its underlying theory is that QoL repre-
sents the capacity of individuals to fulfill their basic 
human needs. Over 20 disease-specific measures have 
been developed that apply the needs-based model.
The CAMPHOR was developed using qualitative 
interviews conducted with PH patients. This ensured 
that only the most appropriate and relevant concerns 
of the patients rather than health professionals were 
included in the measure. The CAMPHOR has been 
shown to have excellent psychometric properties, max-
imizing its ability to detect changes in QoL21. Follow-
ing the development of the CAMPHOR, two other 
PAH specific patient-reported outcome measures have 
been developed: emPHasis-10 questionnaire and 
 Pulmonary Arterial Hypertension-Symptoms and 
Impact Questionnaire (PAH-SYMPACT)®22,23. These 
measures assess patient perceived health status but 
do not collect information on QoL. Therefore, the 
CAMPHOR is the only PAH specific measure that 
integrates the assessment of true QoL.
Prior to this study, the CAMPHOR was not avail-
able in Croatian. We report on the adaptation of the 
CAMPHOR into Croatian and its subsequent valida-
tion. It was intended that the adaptation would pro-
duce a reliable and valid outcome measure for use in 
PH studies in Croatia.
Patients and Methods
Three stages were employed in adapting the 
 CAMPHOR:
•	 translation,
•	 interviews with relevant patients, and
•	 psychometric validation.
Patients were invited to take part in the interviews 
and postal validation survey if they were aged at least 
18 years, were monolingual Croatian speakers, met the 
World Health Organization (WHO) definition of 
PH, and could understand and provide written in-
formed consent. Patients were recruited from the Za-
greb University Hospital Centre in Zagreb. Following 
the Ethics Committee approval, all patients provided 
their written informed consent prior to inclusion in 
the study.
Stage 1: Translation
The CAMPHOR was translated into Croatian us-
ing two separate translation panels24. Firstly, a bilin-
gual panel was held. This consisted of Croatian indi-
viduals whose first language was Croatian and who 
were also fluent in English. The task of this panel was 
to work as a team to translate the UK English version 
of the CAMPHOR into Croatian. The focus was on 
producing conceptual equivalence and a translation 
that would be comprehensible and acceptable to Croa-
tian respondents. If the group differed on the most ap-
propriate wording for an item, alternative potential 
translations were sent to a second panel.
Secondly, a lay panel was held, consisting of six 
monolingual Croatian individuals who were less well 
educated. This panel was employed to ensure that the 
items sounded ‘natural’ and were simple enough for a 
range of potential respondents to understand. The in-
structions and items translated by the bilingual panel 
were presented to members of the lay panel and they 
were asked to check on ease of understanding, and 
whether the wording was appropriate. Where alterna-
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tive translations were presented, participants selected 
the most acceptable one. Both panels were led by the 
same Croatian researcher.
Stage 2: Cognitive debriefing interviews
Ten face to face interviews were conducted with 
relevant patients to determine the face and content va-
lidity of the translated scale. The respondents filled in 
the CAMPHOR in front of the interviewer before 
answering a series of questions about its acceptability 
and comprehensiveness.
Stage 3: Psychometric validation survey
The reliability and validity of the Croatian CAM-
PHOR was tested by means of a postal survey. PH 
patients were invited to take part in the survey. Demo-
graphic data and illness information were collected 
from eligible patients attending the outpatient clinic 
for pulmonary disease at the hospital. At the first ad-
ministration (Time 1), the Croatian CAMPHOR and 
the Croatian version of the SF-3625 were included in 
the postal survey. Respondents who completed and re-
turned both questionnaires were administered the 
CAMPHOR again approximately two weeks later 
(Time 2), to assess reproducibility.
Measures
The CAMPHOR has three individual scales: 
Symptoms (25 items), Activities (15 items) and QoL 
(25 items) (Table 1). The Symptoms scale employs 
“Yes”/”No” format that measures the presence of PH 
symptoms (from 0 to 25). A higher score indicates 
higher symptomatology. The Activities scale assesses 
the extent to which the patient’s daily functioning 
is affected by PH. Each item in the scale has three 
 response options: “Able to do on own without diffi-
culty”, “Able to do on own with difficulty”, and “Un-
able to do on own”. Each item is scored 0 to 2, giving 
a total score of 0 to 30. Poor physical functioning 
is indicated by high scores. The QoL scale uses a 
“True”/”Not true” response format that indicates that 
PH interferes with need fulfillment. Again, a high 
score indicates poorer QoL.
The 36-item Short-Form Health Survey (SF-36)
The SF-36 is a generic HRQL measure containing 
36 items falling into eight sections (physical function-
ing, social functioning, physical role limitations, emo-
tional role limitations, mental health, energy, pain, 
general health and health transition). Each section is 
scored from 0 to 100, but for this measure, a higher 
score indicates better HRQL.
Statistical analyses
Descriptive statistics: Median and inter-quartile 
range [IQR]) scores were calculated for CAMPHOR 
responses, together with floor and ceiling effects.
Internal consistency: Internal consistency was as-
sessed using Cronbach’s alpha, with values below 0.70 
indicating that it would be inappropriate to sum item 
scores26.
Reproducibility: Spearman’s rank correlation coef-
ficient was calculated to establish the test-retest reli-
ability of the CAMPHOR. This estimate of reproduc-
ibility should be 0.85 or above27.
Convergent validity: Convergent validity was de-
termined by correlating scores on the SF-36 sections 
with those on the CAMPHOR scales. It was expected 
that QoL scores would be moderately highly correlat-
ed with the HRQL scores, particularly energy level 
and physical limitations.
Known group validity: Known group validity was 
assessed using Mann-Whitney U tests. These exam-
ined whether the CAMPHOR was able to show 
meaningful differences in score between respondents 
who differed by self-perceived general health (‘very 




I get tired very quickly
(Croatian: Jako brzo se umaram)
I get breathless without doing anything 




Stand for a short time
(Croatian: Kratko stajati)
Lift heavy items
(Croatian: Podizati teške predmete)
Quality  
of Life scale
It feels like my body has let me down 
(Croatian: Osjećam kao da me tijelo 
iznevjerilo)
I feel as if I am a burden to people
(Croatian: Osjećam kao da sam teret 
drugim ljudima)
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good or good’ and ‘fair or poor’) and disease severity 
(‘mild or moderate’ and ‘quite severe or very severe’).
Scores of patients who differed by age (below versus 
above median age) and gender were also examined for 
differences in CAMPHOR scores. As the data col-
lected were at the ordinal level of measurement, non-
parametric statistical tests were employed. The Statis-




Bilingual panel: Two males and four females par-
ticipated in the bilingual panel. They were aged be-
tween 22 and 35 years. The panel found little difficulty 
in producing translation of the CAMPHOR, with 
most items considered straightforward. For some 
items, direct translation of the item was not appropri-
ate. For example, for the item: ‘I feel worn out’, the 
bilingual panel suggested the translation ‘I feel drained/
spent’ to capture the intended meaning of the item.
Lay panel: One male and five females made up the 
lay panel. Their ages ranged from 30 to 76 years. 
Changes were made to the translations where the lay 
panel felt the item could be expressed in more com-
monly used language. For example, ‘I get out of breath 
when I stand up’ from the Symptoms scale was im-
proved by the lay panel. The phrase ‘kad ustanem osta-
nem bez daha’ was replaced with ‘kad ustanem pones-
tane mi daha’ in the lay panel, as the latter was consid-
ered a more natural expression in Croatian.
Stage 2: Cognitive debriefing interviews
Ten cognitive debriefing interviews were perfor-
med (seven female; mean age 39 years). Eight patients 
had idiopathic pulmonary arterial hypertension and 
two had pulmonary hypertension resulting from con-
genital heart disease. Interviewees completed the 
questionnaire between 6 and 11 minutes (mean = 8.8 
minutes).
The mean time taken to complete the CAMPHOR 
was 8.8 (range 6 to 11) minutes. Respondents consid-
ered the questionnaire to be clear, comprehensible and 
relevant. Due attention was paid to three items in the 
cognitive debriefing interviews (CDIs), in which both 
the bilingual and lay panel translations were presented 
Table 2. Demographic and disease information (N=50)
Age Years
Mean (SD) 52.8 (14.4)











Working full-time 6 12
Homemaker 2 4
Retired 29 58





Idiopathic PAH 13 26
PAH due to congenital  
heart disease
14 28










Quite severe 21 42








SD = standard deviation; IQR= interquartile range; PAH = pulmo-
nary arterial hypertension
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to patients for consideration. For two of the items, in-
terviewees felt that the translation generated by the lay 
panel sounded more natural in Croatian. For the item 
‘My condition limits the places I can go’, interviewees 
preferred the bilingual panel’s translation for clarity 
and understanding.
Stage 3: Psychometric validation
All the patients invited agreed to participate in the 
postal validation survey (n=50). Table 2 provides de-
mographic information on the sample and ratings of 
perceived disease severity and general health. Most re-
spondents were female and married or living as mar-
ried. More than half the sample were retired. Most 
patients perceived their disease severity to be ‘moder-
ate’ or ‘quite severe’ and rated their general health as 
‘fair’.
Descriptive statistics
Table 3 shows scores obtained on the outcome 
measures. Large proportions of respondents scored at 
the minimum or maximum on the physical role limita-
tions and emotional role limitations sections of the 
SF-36. The pain section also demonstrated ceiling ef-
fects, indicating that these subscales are not well tar-
geted to PH patients.
Internal consistency and reproducibility
Alpha coefficients and test-retest reliability for 
the CAMPHOR are shown in Tables 4 and 5, respec-
tively. All values achieved were well above the required 
values.
Table 3. Questionnaire descriptive statistics
n Median (IQR) Min - Max % scoring minimum % scoring maximum
Time 1
CAMPHOR Symptoms 47 9 (4-13) 0-24 6 0
CAMPHOR Activities 50 8 (4-13) 1-25 0 0
CAMPHOR QoL 48 5 (2-13) 0-21 13 0
SF-36 sections (Time 1)
Physical functioning 48 55 (30- 69) 0-90 6 0
Physical role limitations 50 25 (0-100) 0-100 36 32
Bodily pain 50 62 (41-100) 12-100 0 28
General health 48 35 (25-59) 5-87 0 0
Vitality 50 53 (40-70) 5-90 0 0
Social functioning 49 63 (50-88) 0-100 4 14
Emotional role limitations 50 100 (33-100) 0-100 22 54
Emotional well-being 50 68 (51-77) 24-100 0 2
Time 2
CAMPHOR Symptoms 49 11 (4-17) 0-25 6 4
CAMPHOR Activities 50 10 (5-14) 0-29 2 0
CAMPHOR QoL 48  7 (2-17) 0-25 15 2
IQR = interquartile range; CAMPHOR = Cambridge Pulmonary Hypertension Outcome Review;  
QoL = quality of life







Correlation coefficient 0.90 0.95 0.90
QoL = quality of life
Table 4. Cronbach’s alpha coefficients
Time 1 Time 2
Symptoms 0.93 0.94
Activities 0.94 0.94
Quality of life 0.92 0.95
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Table 6. Correlation between CAMPHOR scales  
and SF-36 section scores at Time 1
Symptoms Activities Quality  of life
SF-36




Bodily pain -0.62 -0.51 -0.59
General health -0.58 -0.51 -0.64
Vitality -0.74 -0.62 -0.72







All correlations significant at the 0.01 level (2-tailed) except where 
marked; *significant at the 0.05 level (2-tailed)
Fig. 1. Median CAMPHOR scale scores by perceived disease severity.
All comparisons statistically significant (p<0.01; 2-tailed); QoL = quality of life
Convergent validity
Table 6 shows the association between CAM-
PHOR scale scores and those on the SF-36 sections at 
Time 1. CAMPHOR Symptoms were moderately 
highly associated with the SF-36 vitality and physical 
role limitations sections. As expected, CAMPHOR 
Activities were most strongly associated with physical 
functioning. CAMPHOR QoL was most closely re-
lated to scores on the emotional well-being and social 
functioning sections of the SF-36.
Known group validity
There were statistically significant differences in 
scores on all three CAMPHOR scales related to both 
self-perceived disease severity (Fig. 1) and perceived 
overall health (Fig. 2).
Association with demographic factors
Table 7 shows CAMPHOR scores for patients 
grouped by gender and age (below versus above medi-
an age). Scale scores did not differ by gender.
A statistically significant difference between older 
and younger patients was found for the CAMPHOR 
Activities scale. Older patients scored higher on the 
scale than younger patients. This difference was not 
 related to perceived severity of PH (χ² (49)=0.53; 
p=0.47). Similarly, no significant relation was found 
between age and perceived overall health (χ² (50)=2.38; 
p=0.12).
Discussion
The CAMPHOR proved straightforward to adapt 
into Croatian and was found to be easily and quickly 
completed by, and relevant and comprehensive to, local 
PH patients. The adapted CAMPHOR demonstrated 
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good psychometric properties, with excellent consis-
tency and test-retest reliability. Tests of validity showed 
that CAMPHOR scale scores correlated as expected 
with SF-36 section scores and were able to distinguish 
between groups of patients who varied by perceived 
disease severity and general health.
Without careful adaptation, questionnaire items 
may be interpreted differently by local respondents or 
the instructions could cause problems. This study em-
ployed two translation panels24. This approach focuses 
on conceptual equivalence to the source measure rath-
er than literal equivalence. Consequently, language 
versions are produced that are more directly compara-
ble. Patients have rated translations produced by this 
dual-panel methodology as preferable to those devel-
oped using forward-backward translations29. Because 
of the numerous dialects in Croatia, it was important 
that the adaptation was expressed in simple, everyday 
language. Participants in the bilingual and lay panels 
were mainly from one region in Croatia, meaning it is 
possible that the translations would not be appropriate 
for all regional dialects. However, the psychometric 
validation stage included participants from through-
out the country and no problems with the wording of 
items were found.
Given that elderly populations tend to have poor 
physical functioning, it is not surprising that differ-
ences in scores on the CAMPHOR Activities scale 
Fig. 2. Median CAMPHOR scale scores by perceived general health.
All comparisons statistically significant (p<0.001; 2-tailed); QoL = quality of life
Table 7. CAMPHOR scale scores by gender and age group
Symptoms Activities QoL
n Median (IQR) n Median (IQR) n Median (IQR)
Gender
Male 15 9 (6-17) 15 12 (7-15) 14 10 (3-17)
Female 32 9 (3-13) 35 7 (4-11) 34 5 (2-11)
p 47 0.42 50 0.14 48 0.26
Age
Below median 25 7 (4-13) 25 6 (3-9) 24 5 (1-10)
Above median 22 10 (6-18) 25 12 (7-17) 24 7 (4-16)
p 0.25 <0.05 0.07
IQR = interquartile range; QoL = quality of life
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were found between older and younger patients. This 
finding could not be explained in terms of differences 
in patient-perceived disease severity or general health, 
suggesting that care should be taken when matching 
comparison groups in clinical studies.
A limitation of the study was that most of the par-
ticipants in the bilingual panel were university stu-
dents. Consequently, it is possible that the first transla-
tion produced may have been more appropriate to a 
younger population. However, any resulting issues 
were dealt with in the lay panel which consisted of 
people with a wider range of ages.
The Croatian CAMPHOR is one of many lan-
guage adaptations that have been produced, all of 
which have been shown to have good psychometric 
properties. Results in this study compared well with 
those for the German30, Swedish31, Canadian32, United 
States33, and Australian and New Zealand34 adapta-
tions of the CAMPHOR. Use of the CAMPHOR in 
everyday practice may facilitate communication be-
tween clinicians and patients.
Conclusion
The newly developed Croatian CAMPHOR rep-
resents an accurate and reliable instrument for assess-
ing both HRQL and QoL in Croatian PH patients. 
The new questionnaire will prove a valuable tool for 
application in clinical routine and for evaluating clini-
cal and non-clinical interventions.
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Sažetak
HRVATSKA PRILAGODBA I VREDNOVANJE UPITNIKA  
THE CAMBRIDGE PULMONARY HYPERTENSION OUTCOME REVIEW (CAMPHOR)
A. Hećimović, A. Heaney, S.P. McKenna, L. Basara, M. Jakopović, A. Vukić Dugac, G. Redžepi,  
C. Rotim, M. Samaržija, N. Jokić-Begić i S. Popović-Grle
Plućna hipertenzija je kronična bolest koja značajno narušava kvalitetu života. The Cambridge Pulmonary Hypertension 
Outcome Review (CAMPHOR) je prvi upitnik specifičan za ovu bolest kojim bolesnici s plućnom hipertenzijom smoprocje-
njuju simptome, funkcionalni status i kvalitetu života. Cilj ove studije bio je prilagoditi i vrednovati CAMPHOR za uporabu 
u Republici Hrvatskoj. Prilagodba je postupak koji uključuje tri koraka: prijevod (dvojezični panel i panel laika), kognitivno 
ispitivanje i psihometrijsko vrednovanje. U daljnjem tijeku ispitivanje je provedeno na 50 bolesnika kako bi se ispitala pouz-
danost i valjanost adaptiranih ljestvica. Sve tri ljestvice hrvatske verzije CAMPHOR-a pokazale su izvrsnu unutarnju kon-
zistenciju (Simptomi = 0,93; Aktivnosti = 0,95; Kvaliteta života = 0,92) i ponovljivost (Simptomi = 0,90; Aktivnosti = 0,95; 
Kvaliteta života = 0,92). Korelacija sa česticama SF-36 potvrdila je strukturnu valjanost ljestvica CAMPHOR-a. Prema 
 rezultatima ljestvica moguće je razlikovati ispitanike grupirane prema samoprocijenjenom općem zdravstvenom stanju i 
 težini bolesti, čime je dokazana valjanost upitnika za definirane skupine. Hrvatska inačica CAMPHOR-a je valjan i pouzdan 
upitnik za primjenu u svakodnevnom kliničkom radu i kliničkim ispitivanjima.
Ključne riječi: Hipertenzija, plućna; Kvaliteta života; Hrvatska; Reproducibilnost rezultata; Ankete i upitnici
